Sipuleucel-T for the treatment of prostate cancer.
Patients with cancer have deficiencies in the number and function of dendritic cells. Loaded dendritic cell therapies attempt to overcome these deficiencies by exposing antigen-presenting cells to antigens ex vivo. Sipuleucel-T (APC-8015) is a novel immunotherapeutic consisting of autologous dendritic cells which have been pulsed ex vivo with PA2024 as a source of antigen. PA2024 is a recombinant fusion protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) and prostatic acid phosphatase. One phase III randomized clinical trial has demonstrated a survival benefit in patients with metastatic hormone-refractory prostate cancer, but additional information is needed before FDA approval. This review summarizes the clinical trials evaluating sipuleucel-T and discusses its potential role in the treatment of prostate cancer.
Harzstark
Andrea L
AL
Department of Medicine, University of California, San Francisco, California, USA.
Small
Eric J
EJ
D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D014020:Tissue Extracts / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use*
D014020:Tissue Extracts; C511774:sipuleucel-T